Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line treatment for chronic spontaneous urticaria (CSU), also known as chronic hives.

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new candidate ...

About HIVE Digital Technologies Ltd. HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Artur is a copywriter and SEO specialist, as well as a small business owner. In his free time, he loves to play computer games and is glad that he was able to connect his professional career with his ...

Common food allergies include dairy, peanuts, and tree nuts, among others. You may be more likely to outgrow certain allergies than others. A food allergy is a condition in which certain foods trigger ...

If you have health anxiety, you know that nothing can derail a day like a new, unexplained skin rash. That’s because there can be *a lot* of causes, and well, you probably want to take care of it ASAP ...